Chronische myeloische Leukämie

Literatur

• 1 Baccarani M, Cortes J, Pane F. et al . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.  J Clin Oncol. 2009;  27 6041-6051
  Google Scholar
• 2 Burchert A, Müller M C, Kostrewa P. et al . Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.  J Clin Oncol. 2010;  28 1429-1435
  Google Scholar
• 3 Cortes J E, Baccarani M, Guilhot F. et al . Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.  J Clin Oncol. 2010;  28 424-430
  Google Scholar
• 4 Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.  J Clin Oncol. 2011;  29 524-531
  Google Scholar
• 5 Hasford J, Baccarani M, Hoffmann V. et al . Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.  Blood. 2011;  118 686-692
  Google Scholar
• 6 Hehlmann R, Lauseker M, Jung-Munkwitz S. et al . Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-a in newly diagnosed chronic myeloid leukemia.  J Clin Oncol. 2011;  29 1634-1642
  Google Scholar
• 7 Hochhaus A, La Rosée P, Müller M C, Ernst T, Cross N C. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.  Cell Cycle. 2011;  10 250-260
  Google Scholar
• 8 Hughes T P, Hochhaus A, Branford S. et al . Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).  Blood. 2010;  116 3758-3765
  Google Scholar
• 9 Kantarjian H, Shah N P, Hochhaus A. et al . Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.  N Engl J Med. 2010;  362 2260-2270
  Google Scholar
• 10 Mahon F X, Réa D, Guilhot J. et al . Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.  Lancet Oncol. 2010;  11 1029-1035
  Google Scholar
• 11 Marin D, Bazeos A, Mahon F X. et al . Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.  J Clin Oncol. 2010;  28 2381-2388
  Google Scholar
• 12 Müller M C, Cross N C, Erben P. et al . Harmonization of molecular monitoring of CML therapy in Europe.  Leukemia. 2009;  23 1957-1963
  Google Scholar
• 13 Preudhomme C, Guilhot J, Nicolini F E. et al . Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.  N Engl J Med. 2010;  363 2511-2521
  Google Scholar
• 14 Saglio G, Kim D W, Issaragrisil S. et al . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.  N Engl J Med. 2010;  362 2251-2259
  Google Scholar
• 15 Simonsson B, Gedde-Dahl T, Markevärn B. et al . Combination of pegylated interferon-a2b with imatinib increases molecular response rates in patients with low or intermediate risk chronic myeloid leukemia.  Blood. 2011 Jun 17 ;  [Epub ahead of print]
  Google Scholar

Prof. Dr. Andreas Hochhaus

Universitätsklinikum Jena
Klinik für Innere Medizin II,
Abteilung Hämatologie und internistische Onkologie

Erlanger Allee 101

07740 Jena

Phone: 03641/932 4201

Fax: 03641/932 4202

Email: andreas.hochhaus@med.uni-jena.de